Phase 3 Data Suggest Potential New Therapeutic Option for TNBC
Short-term results from the CamRelief phase 3 trial show that neoadjuvant camrelizumab (AiRuiKa) plus chemotherapy improves the rate of pathological…
Short-term results from the CamRelief phase 3 trial show that neoadjuvant camrelizumab (AiRuiKa) plus chemotherapy improves the rate of pathological…
An analysis of the chemotherapy cohort from the ADAPT trial found that nanoparticle albumin-bound (nab)-paclitaxel (PAC) had similar outcomes to…
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!